CID SpA, a leading European company in interventional therapies, sponsors a major Symposium at Euro PCR 2012 entitled "Cre8™: the effective DES solution with no safety concerns". This event will take place on Tuesday 15th of May from 14:00 to 15:30 – Room 252AB – Palais des Congrès – Paris.

During the symposium a summary of CID’s Cre8TM Drug Eluting Stent (DES) technology together with all the available clinical data will be presented. The distinctive features of the Cre8™ technology may represent a new standard in terms of efficacy and safety, thanks to the polymer-free platform; the Bio Inducer Surface and the Abluminal Reservoir Technology that elutes the new AmphilimusTM formulation.

The clinical plan of Cre8™ will also be presented, highlighting the two main objectives pursued by the company. The first is related to the research of a superior DES efficacy in the complex setting of diabetic patients, while the second is associated to unmet DES safety and DAT duration.

Diabetes is one of the leading causes of death and 2/3 of these are due to coronary artery disease. PCI in diabetic patients still represents an area for improvement in current generation devices, in fact patient outcomes are poorer in comparison to those of non-diabetic patients. 1st and 2nd generation DES’s have not yet provided the expected results in terms of efficacy.

Regarding PCI safety, DAT duration still represents an open question in DES implantation. It is mandatory to consider the balance between the risk of stent thrombosis and the rate of bleeding events, taking into account the growing complexity of the PCI population and its co-morbidity this population has.

Cre8’s on-going and planned studies are focused on the two fundamental needs stated above and have been specifically designed to confirm the very positive initial findings available today.

Source: CID SpA